Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Zhenlei Yang, Liu Tian, Jingjing Liu & Guihua Huang. (2018) Construction and evaluation in vitro and in vivo of tedizolid phosphate loaded cationic liposomes. Journal of Liposome Research 28:4, pages 322-330.
Read now
Read now
Olivia Ferrández, Olatz Urbina & Santiago Grau. (2017) Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Design, Development and Therapy 11, pages 65-82.
Read now
Read now
Darrell McBride, Tamara Krekel, Kevin Hsueh & Michael J. Durkin. (2017) Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections. Expert Opinion on Drug Metabolism & Toxicology 13:3, pages 331-337.
Read now
Read now
Cuong Vuong, Anthony J. Yeh, Gordon YC Cheung & Michael Otto. (2016) Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opinion on Investigational Drugs 25:1, pages 73-93.
Read now
Read now
Tamara Nawar & Zeina A Kanafani. (2015) Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections. Expert Review of Anti-infective Therapy 13:7, pages 825-833.
Read now
Read now
Lee P Skrupky, Bethany R Tellor & John E Mazuski. (2013) Current strategies for the treatment of complicated intraabdominal infections. Expert Opinion on Pharmacotherapy 14:14, pages 1933-1947.
Read now
Read now
Jeffrey M Rybak, Katie E Barber & Michael J Rybak. (2013) Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opinion on Pharmacotherapy 14:14, pages 1919-1932.
Read now
Read now
Adamantia Liapikou & Antoni Torres. (2013) Emerging drugs on methicillin-resistant Staphylococcus aureus
. Expert Opinion on Emerging Drugs 18:3, pages 291-305.
Read now
Read now
Articles from other publishers (48)
Guilherme Felipe Santos Fernandes, Cauê Benito Scarim, Seong-Heun Kim, Jingyue Wu & Daniele Castagnolo. (2023) Oxazolidinones as versatile scaffolds in medicinal chemistry. RSC Medicinal Chemistry 14:5, pages 823-847.
Crossref
Crossref
Parteek Prasher, Tanisqa Mall & Mousmee Sharma. (2023) Cyclic carbamates in medicine: A clinical perspective. Drug Development Research 84:3, pages 397-405.
Crossref
Crossref
Zeinab Breijyeh & Rafik Karaman. (2023) Design and Synthesis of Novel Antimicrobial Agents. Antibiotics 12:3, pages 628.
Crossref
Crossref
Haijia Lu, Huahao Wang, Hongyi Zhao & Dongfeng Zhang. (2022) Recent advances in oxazolidinones as antituberculosis agents. Future Medicinal Chemistry 14:15, pages 1149-1165.
Crossref
Crossref
Audrey R. N. Ndukwe, Sandra Wiedbrauk, Nathan R. B. Boase & Kathryn E. Fairfull‐Smith. (2022) Strategies to Improve the Potency of Oxazolidinones towards Bacterial Biofilms. Chemistry – An Asian Journal 17:11.
Crossref
Crossref
Yuki Sato, Yoh Takekuma, Takayuki Daisho, Hitoshi Kashiwagi, Shungo Imai & Mitsuru Sugawara. (2022) Development of a Method of Liquid Chromatography Coupled with Tandem Mass Spectrometry for Simultaneous Determination of Linezolid and Tedizolid in Human Plasma. Biological and Pharmaceutical Bulletin 45:4, pages 421-428.
Crossref
Crossref
Prashant S. Mandal & A. Vijay Kumar. (2022) Metal‐Free One‐Pot Domino Synthesis of Oxazolidinone Derivatives. Asian Journal of Organic Chemistry 11:3.
Crossref
Crossref
Surajit Duari, Subrata Biswas, Arnab Roy, Srabani Maity, Abhishek Kumar Mishra, Aguinaldo R. Souza, Asma M. Elsharif, Nelson H. Morgon & Srijit Biswas. (2022) Regioselective N‐Functionalization of Tautomerizable Heterocycles through Methyl Trifluoromethanesulfonate‐Catalyzed Substitution of Alcohols and Alkyl Group Migrations. Advanced Synthesis & Catalysis 364:4, pages 865-872.
Crossref
Crossref
Vinod K. Ahirrao, Rushikesh H. Patil, Amin R. Pathan, Kiran R. Patil, Vipul P. Rane & Ravindra D. Yeole. (2021) Impurity Profiling of Novel Oxazolidinone Antibacterial Agent: WCK 4086. Chromatographia 84:12, pages 1121-1130.
Crossref
Crossref
Christophe R Cantelli, Alexandra Dassonville-Klimpt & Pascal Sonnet. (2021) A review of current and promising nontuberculous mycobacteria antibiotics. Future Medicinal Chemistry 13:16, pages 1367-1395.
Crossref
Crossref
Shera Tan & Shannon Kasperbauer. (2021) Nontuberculous Mycobacteria. Seminars in Respiratory and Critical Care Medicine 42:04, pages 567-586.
Crossref
Crossref
Laiying Zhang, Jun He, Lang Bai, Shihua Ruan, Tao Yang & Youfu Luo. (2021) Ribosome‐targeting antibacterial agents: Advances, challenges, and opportunities. Medicinal Research Reviews 41:4, pages 1855-1889.
Crossref
Crossref
Wen Wang, Kate M. Voss, Jinqian Liu & Mikhail F. Gordeev. (2021) Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chemical Research in Toxicology 34:5, pages 1348-1354.
Crossref
Crossref
Klaudia T. Angula, Lesetja J. Legoabe & Richard M. Beteck. (2021) Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review. Pharmaceuticals 14:5, pages 461.
Crossref
Crossref
Mohd Abul Kalam, Muzaffar Iqbal, Abdullah Alshememry, Musaed Alkholief & Aws Alshamsan. (2021) UPLC-MS/MS assay of Tedizolid in rabbit aqueous humor: Application to ocular pharmacokinetic study. Journal of Chromatography B 1171, pages 122621.
Crossref
Crossref
Aurélie Chauffour, Jérôme Robert, Nicolas Veziris, Alexandra Aubry, Kevin Pethe & Vincent Jarlier. (2020) Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLOS Neglected Tropical Diseases 14:8, pages e0007857.
Crossref
Crossref
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, Stefano Perito, Daniela Francisci, Franco Baldelli & Claudia Monari. (2020) Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm. Frontiers in Microbiology 11.
Crossref
Crossref
Buthaina Jubeh, Zeinab Breijyeh & Rafik Karaman. (2020) Antibacterial Prodrugs to Overcome Bacterial Resistance. Molecules 25:7, pages 1543.
Crossref
Crossref
Vinod Ahirrao, Vipul Rane, Kiran Patil, Rajiv Jadhav, Anasuya Patel, Vijay Patil & Ravindra Yeole. (2019) Chiral separation and thermodynamic investigation of WCK 3023: A novel oxazolidinone antibacterial agent, application to pre‐clinical pharmacokinetic study. Biomedical Chromatography 33:9.
Crossref
Crossref
Pilar Ruiz, Manuel Causse, Manuel Vaquero & Manuel Casal. (2019)
In Vitro
Activity of Tedizolid against
Mycobacterium tuberculosis
. Antimicrobial Agents and Chemotherapy 63:4.
Crossref
Crossref
Vinod K Ahirrao, Vipul P Rane, Kiran R Patil, Vijay J Patil, Ravindra D Yeole & Mahesh V Patel. (2018) Development and Validation of the Chiral Liquid Chromatography Method for Separation of Enantiomeric Impurity in Novel Oxazolidinone Antibacterial Agent WCK 4086. Journal of Chromatographic Science 56:9, pages 789-793.
Crossref
Crossref
Jordan R. Smith, Juwon Yim, Seth Rice, Kyle Stamper, Razie Kebriaei & Michael J. Rybak. (2018)
Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an
In Vitro
Model of Simulated Endocardial Vegetations
. Antimicrobial Agents and Chemotherapy 62:5.
Crossref
Crossref
Barbara A. Brown-Elliott & Richard J. WallaceJr.Jr.. (2017)
In Vitro
Susceptibility Testing of Tedizolid against Isolates of Nocardia
. Antimicrobial Agents and Chemotherapy 61:12.
Crossref
Crossref
Yun Kim, Anhye Kim, SeungHwan Lee, Sung-Hak Choi, Dae Young Lee, Ji-Su Song, Howard Lee, In-Jin Jang & Kyung-Sang Yu. (2017) Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects. Clinical Therapeutics 39:9, pages 1849-1857.
Crossref
Crossref
Sean M. Kelly, Chong Han, Laura Tung & Francis Gosselin. (2017) Chemoselective Copper-Catalyzed Ullmann-Type Coupling of Oxazolidinones with Bromoiodoarenes. Organic Letters 19:11, pages 3021-3024.
Crossref
Crossref
Barbara A. Brown-Elliott & Richard J. WallaceJr.Jr.. (2017)
In Vitro
Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria
. Journal of Clinical Microbiology 55:6, pages 1747-1754.
Crossref
Crossref
Yinping Lei, Bo Jin, Chen Ma, Tingting Zhang & Tong Li. (2017) Identification of forced degradation products of tedizolid phosphate by liquid chromatography/electrospray ionization tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 139, pages 221-231.
Crossref
Crossref
Santiago Pérez-Parra, Alejandro Peña-Monje, Juan Luis Recio & Federico García-García. (2017) Comparative activity of tedizolid against clinical isolates of linezolid-resistant coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus. Enfermedades infecciosas y microbiologia clinica (English ed.) 35:5, pages 323-324.
Crossref
Crossref
Santiago Pérez-Parra, Alejandro Peña-Monje, Juan Luis Recio & Federico García-García. (2017) Actividad comparativa de tedizolid frente a Staphylococcus coagulasa negativos resistentes a linezolid y Staphylococcus aureus resistentes a meticilina. Enfermedades Infecciosas y Microbiología Clínica 35:5, pages 323-324.
Crossref
Crossref
Aasiya Matin, Smriti Sharma, Pankaj Mathur & Senu K. Apewokin. (2017) Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report. International Journal of Antimicrobial Agents 49:4, pages 488-492.
Crossref
Crossref
D. J. Biedenbach, S. K. Bouchillon, B. Johnson, J. Alder & D. F. Sahm. (2016) In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China. European Journal of Clinical Microbiology & Infectious Diseases 35:12, pages 1933-1939.
Crossref
Crossref
Shuguang Li, Yu Guo, Chunjiang Zhao, Hongbin Chen, Bijie Hu, Yunzhuo Chu, Zhijie Zhang, Yunjian Hu, Zhiyong Liu, Yan Du, Qiaodi Gui, Ping Ji, Ji Zeng, Bin Cao, Quan Fu, Rong Zhang, Zhongxin Wang, Chao Zhuo, Xianju Feng, Wei Jia, Yan Jin, Xuesong Xu, Kang Liao, Yuxing Ni, Yunsong Yu, Xiuli Xu, Zhidong Hu, Jin-E Lei, Qing Yang & Hui Wang. (2016) In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China. Journal of Medical Microbiology 65:10, pages 1215-1224.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2016) Synthetic approaches to the 2014 new drugs. Bioorganic & Medicinal Chemistry 24:9, pages 1937-1980.
Crossref
Crossref
Yu Zhou, Jiang Wang, Zhanni Gu, Shuni Wang, Wei Zhu, José Luis Aceña, Vadim A. Soloshonok, Kunisuke Izawa & Hong Liu. (2016) Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chemical Reviews 116:2, pages 422-518.
Crossref
Crossref
Jesse A. Jones, Kristopher G. Virga, Giuseppe Gumina & Kirk E. Hevener. (2016) Recent advances in the rational design and optimization of antibacterial agents. MedChemComm 7:9, pages 1694-1715.
Crossref
Crossref
George G. Zhanel, Riley Love, Heather Adam, Alyssa Golden, Sheryl Zelenitsky, Frank Schweizer, Bala Gorityala, Philippe R. S. Lagacé-Wiens, Ethan Rubinstein, Andrew Walkty, Alfred S. Gin, Matthew Gilmour, Daryl J. Hoban, Joseph P. Lynch3rd3rd & James A. Karlowsky. (2015) Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. Drugs 75:3, pages 253-270.
Crossref
Crossref
S. Flanagan, S. L. Minassian, D. Morris, R. Ponnuraj, T. C. Marbury, H. W. Alcorn, E. Fang & P. Prokocimer. (2014) Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment. Antimicrobial Agents and Chemotherapy 58:11, pages 6471-6476.
Crossref
Crossref
Pauline Guillard, Arnaud de La Blanchardière, Vincent Cattoir, Marc-Olivier Fischer, Renaud Verdon & Guillaume Saint-Lorant. (2014) Antimicrobial stewardship and linezolid. International Journal of Clinical Pharmacy 36:5, pages 1059-1068.
Crossref
Crossref
Voon Ong, Shawn Flanagan, Edward Fang, Howard J. Dreskin, Jeffrey B. Locke, Kenneth Bartizal & Philippe Prokocimer. (2014) Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate. Drug Metabolism and Disposition 42:8, pages 1275-1284.
Crossref
Crossref
Wanida Phetsang, Mark A.T. Blaskovich, Mark S. Butler, Johnny X. Huang, Johannes Zuegg, Sreeman K. Mamidyala, Soumya Ramu, Angela M. Kavanagh & Matthew A. Cooper. (2014) An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants. Bioorganic & Medicinal Chemistry 22:16, pages 4490-4498.
Crossref
Crossref
Mikhail F. Gordeev & Zhengyu Y. Yuan. (2014) New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile. Journal of Medicinal Chemistry 57:11, pages 4487-4497.
Crossref
Crossref
Jamie J. KisgenHanine MansourNathan R. UngerLindsey M. Childs. (2014) Tedizolid: A new oxazolidinone antimicrobial. American Journal of Health-System Pharmacy 71:8, pages 621-633.
Crossref
Crossref
Hong Lei, Ying Jiang, Di Wang, Ping Gong, Yanyan Li, Yueming Dong & Mei Dong. (2014) In Vitro Activity of Novel Oxazolidinone Analogs and 13 Conventional Antimicrobial Agents against Clinical Isolates of Staphylococcus aureus in Beijing, China. Japanese Journal of Infectious Diseases 67:5, pages 402-404.
Crossref
Crossref
D. Das, P. M. Tulkens, P. Mehra, E. Fang & P. Prokocimer. (2013) Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Safety Summary. Clinical Infectious Diseases 58:suppl 1, pages S51-S57.
Crossref
Crossref
W. O'Riordan, S. Green, P. Mehra, C. De Anda, E. Fang & P. Prokocimer. (2013) Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Efficacy Summary. Clinical Infectious Diseases 58:suppl 1, pages S43-S50.
Crossref
Crossref
Jeffrey B. Locke, Gary E. Zurenko, Karen Joy Shaw & Kenneth Bartizal. (2014) Tedizolid for the Management of Human Infections: In Vitro Characteristics. Clinical Infectious Diseases 58:suppl_1, pages S35-S42.
Crossref
Crossref
Michael J. Pucci & Karen Bush. (2013) Investigational Antimicrobial Agents of 2013. Clinical Microbiology Reviews 26:4, pages 792-821.
Crossref
Crossref
Mark S Butler, Mark A Blaskovich & Matthew A Cooper. (2013) Antibiotics in the clinical pipeline in 2013. The Journal of Antibiotics 66:10, pages 571-591.
Crossref
Crossref